DDI2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: HL60 and Jurkat cell lysates, Primary antibody: P09598(DDI2 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09598(DDI2 Antibody) at dilution 1/75. (Original magnification: ×200)    

  
  

The DDI2 (DNA-damage inducible protein 1 homolog 2) antibody is a research tool targeting the DDI2 protein, a key regulator in cellular stress response pathways. DDI2. a member of the aspartic protease family, plays a critical role in activating the transcription factor Nrf1 (NFE2L1) under proteasome dysfunction. When proteasome activity is impaired, DDI2 cleaves Nrf1 from the endoplasmic reticulum membrane, enabling its translocation to the nucleus to initiate the transcription of proteasome subunit genes, thereby restoring proteostasis. This DDI2-Nrf1 axis is vital for maintaining cellular adaptation to oxidative stress, protein aggregation, and proteotoxic conditions.

DDI2 antibodies are widely used in studies investigating protein quality control mechanisms, neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), and cancer, where proteasome inhibition therapies (e.g., bortezomib) are employed. Researchers utilize these antibodies in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect DDI2 expression levels, subcellular localization, and its interaction with Nrf1. Recent studies also explore DDI2’s potential role in drug resistance, as cancer cells may exploit the DDI2-Nrf1 pathway to counteract proteasome inhibitor treatments. Commercial DDI2 antibodies are typically validated for specificity in human, mouse, or rat models, aiding mechanistic insights into proteasome regulation and stress adaptation.